{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:50:18Z","timestamp":1784238618087,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"EU-NextGenerationEU and the Recovery, Transformation, and Resilience Plan, granted to the Ministry of Employment, Training, and Autonomous Work","award":["SE\/INV\/0008\/2022"],"award-info":[{"award-number":["SE\/INV\/0008\/2022"]}]},{"name":"EU-NextGenerationEU and the Recovery, Transformation, and Resilience Plan, granted to the Ministry of Employment, Training, and Autonomous Work","award":["SE\/INV\/0008\/2022"],"award-info":[{"award-number":["SE\/INV\/0008\/2022"]}]},{"name":"EU-NextGenerationEU and the Recovery, Transformation, and Resilience Plan, granted to the Ministry of Employment, Training, and Autonomous Work","award":["SE\/INV\/0008\/2022"],"award-info":[{"award-number":["SE\/INV\/0008\/2022"]}]},{"name":"EU-NextGenerationEU and the Recovery, Transformation, and Resilience Plan, granted to the Ministry of Employment, Training, and Autonomous Work","award":["SE\/INV\/0008\/2022"],"award-info":[{"award-number":["SE\/INV\/0008\/2022"]}]},{"name":"EU-NextGenerationEU and the Recovery, Transformation, and Resilience Plan, granted to the Ministry of Employment, Training, and Autonomous Work","award":["SE\/INV\/0008\/2022"],"award-info":[{"award-number":["SE\/INV\/0008\/2022"]}]},{"name":"Sociedad Andaluza de Patolog\u00eda Digestiva through the Beca del Grupo Andaluz de Trabajo de Enfermedad Inflamatoria Intestinal 2022"},{"DOI":"10.13039\/100022924","name":"Grupo Espa\u00f1ol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100022924","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-25370-0","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T11:55:10Z","timestamp":1763726110000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Identifying key clinical and biochemical predictors of treatment outcomes in inflammatory bowel disease: a real-world evidence study"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3538-1795","authenticated-orcid":false,"given":"Juan Luis Gonz\u00e1lez","family":"Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5370-4891","authenticated-orcid":false,"given":"Carmen V\u00edas","family":"Parrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6223-3844","authenticated-orcid":false,"given":"Jaime","family":"Cordero-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3932-6417","authenticated-orcid":false,"given":"Ahmed","family":"Bouallou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7012-2973","authenticated-orcid":false,"given":"Miguel \u00c1ngel","family":"Armengol de la Hoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3646-8919","authenticated-orcid":false,"given":"Federico Arg\u00fcelles","family":"Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"issue":"4","key":"25370_CR1","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/ajg.2011.103","volume":"106","author":"H Yanai","year":"2011","unstructured":"Yanai, H. & Hanauer, S. B. Assessing response and loss of response to biological therapies in IBD. Am. J. Gastroenterol. 106(4), 685\u2013698. https:\/\/doi.org\/10.1038\/ajg.2011.103 (2011).","journal-title":"Am. J. Gastroenterol."},{"issue":"27","key":"25370_CR2","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383(27), 2603\u20132615. https:\/\/doi.org\/10.1056\/NEJMoa2034577 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"25370_CR3","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1093\/ecco-jcc\/jjz195","volume":"14","author":"JP Gisbert","year":"2020","unstructured":"Gisbert, J. P. & Chaparro, M. Predictors of primary response to biologic treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in patients with inflammatory bowel disease: From basic science to clinical practice. J. Crohns Colitis 14(5), 694\u2013709. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz195 (2020).","journal-title":"J. Crohns Colitis"},{"issue":"6","key":"25370_CR4","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1093\/ibd\/izab187","volume":"28","author":"A Javaid","year":"2021","unstructured":"Javaid, A. et al. Machine learning predictive outcomes modeling in inflammatory bowel diseases. Inflamm. Bowel Dis. 28(6), 819\u2013829. https:\/\/doi.org\/10.1093\/ibd\/izab187 (2021).","journal-title":"Inflamm. Bowel Dis."},{"issue":"7","key":"25370_CR5","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1093\/ecco-jcc\/jjx014","volume":"11","author":"AK Waljee","year":"2017","unstructured":"Waljee, A. K. et al. Machine learning algorithms for objective remission and clinical outcomes with Thiopurines. J. Crohns Colitis 11(7), 801\u2013810. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx014 (2017).","journal-title":"J. Crohns Colitis"},{"issue":"5","key":"25370_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.3721","volume":"2","author":"AK Waljee","year":"2019","unstructured":"Waljee, A. K. et al. Development and validation of machine learning models in prediction of remission in patients with moderate to severe Crohn disease. JAMA Netw. Open 2(5), e193721. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.3721 (2019).","journal-title":"JAMA Netw. Open"},{"issue":"15","key":"25370_CR7","doi-asserted-by":"publisher","first-page":"4518","DOI":"10.3390\/jcm11154518","volume":"11","author":"M Chaparro","year":"2022","unstructured":"Chaparro, M. et al. Using interpretable machine learning to identify baseline predictive factors of remission and drug durability in Crohn\u2019s disease patients on Ustekinumab. J. Clin. Med. 11(15), 4518. https:\/\/doi.org\/10.3390\/jcm11154518 (2022).","journal-title":"J. Clin. Med."},{"issue":"6","key":"25370_CR8","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1093\/ibd\/izy031","volume":"24","author":"AK Waljee","year":"2018","unstructured":"Waljee, A. K. et al. Predicting corticosteroid-free biologic remission with Vedolizumab in Crohn\u2019s disease. Inflamm. Bowel Dis. 24(6), 1185\u20131192. https:\/\/doi.org\/10.1093\/ibd\/izy031 (2018).","journal-title":"Inflamm. Bowel Dis."},{"issue":"10","key":"25370_CR9","doi-asserted-by":"publisher","first-page":"4874","DOI":"10.1007\/s10620-022-07506-8","volume":"67","author":"A Zand","year":"2022","unstructured":"Zand, A., Stokes, Z., Sharma, A., van Deen, W. K. & Hommes, D. Artificial intelligence for inflammatory bowel diseases (IBD): accurately predicting adverse outcomes using machine learning. Dig. Dis. Sci. 67(10), 4874\u20134885. https:\/\/doi.org\/10.1007\/s10620-022-07506-8 (2022).","journal-title":"Dig. Dis. Sci."},{"issue":"3","key":"25370_CR10","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/ecco-jcc\/jjab155","volume":"16","author":"NH Nguyen","year":"2022","unstructured":"Nguyen, N. H. et al. Machine learning-based prediction models for diagnosis and prognosis in inflammatory bowel diseases: A systematic review. J. Crohns Colitis 16(3), 398\u2013413. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab155 (2022).","journal-title":"J. Crohns Colitis"},{"key":"25370_CR11","unstructured":"Anuj, \u2018F1 Score in Machine Learning\u2019, Machine Learning Architect. Accessed: 03 Dec 2024. [Online]. Available: https:\/\/machinelearningarchitect.com\/machine-learning-basics\/f1-score-in-machine-learning\/"},{"key":"25370_CR12","doi-asserted-by":"publisher","unstructured":"T. Chen and C. Guestrin, \u2018XGBoost: A Scalable Tree Boosting System\u2019, in Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, in KDD \u201916. New York, NY, USA: Association for Computing Machinery, Aug. 2016, pp. 785\u2013794. https:\/\/doi.org\/10.1145\/2939672.2939785.","DOI":"10.1145\/2939672.2939785"},{"key":"25370_CR13","doi-asserted-by":"publisher","unstructured":"S. Champely, \u2018pwr: Basic Functions for Power Analysis\u2019. p. 1.3\u20130, 2006. https:\/\/doi.org\/10.32614\/CRAN.package.pwr.","DOI":"10.32614\/CRAN.package.pwr"},{"issue":"1","key":"25370_CR14","doi-asserted-by":"publisher","first-page":"16440","DOI":"10.1038\/s41598-021-96019-x","volume":"11","author":"J Miyoshi","year":"2021","unstructured":"Miyoshi, J. et al. Machine learning using clinical data at baseline predicts the efficacy of vedolizumab at week 22 in patients with ulcerative colitis. Sci. Rep. 11(1), 16440. https:\/\/doi.org\/10.1038\/s41598-021-96019-x (2021).","journal-title":"Sci. Rep."},{"issue":"27","key":"25370_CR15","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1056\/NEJMra2002697","volume":"383","author":"JT Chang","year":"2020","unstructured":"Chang, J. T. Pathophysiology of Inflammatory Bowel Diseases. N. Engl. J. Med. 383(27), 2652\u20132664. https:\/\/doi.org\/10.1056\/NEJMra2002697 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"25370_CR16","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.3390\/nu15173824","volume":"15","author":"M Valvano","year":"2023","unstructured":"Valvano, M. et al. Nutrition, nutritional status, micronutrients deficiency, and disease course of inflammatory bowel disease. Nutrients 15(17), 3824. https:\/\/doi.org\/10.3390\/nu15173824 (2023).","journal-title":"Nutrients"},{"issue":"31","key":"25370_CR17","doi-asserted-by":"publisher","first-page":"4481","DOI":"10.3748\/wjg.v25.i31.4481","volume":"25","author":"P Hoffmann","year":"2019","unstructured":"Hoffmann, P. et al. Ustekinumab: \u201cReal-world\u201d outcomes and potential predictors of nonresponse in treatment-refractory Crohn\u2019s disease. World J. Gastroenterol. 25(31), 4481\u20134492. https:\/\/doi.org\/10.3748\/wjg.v25.i31.4481 (2019).","journal-title":"World J. Gastroenterol."},{"issue":"12","key":"25370_CR18","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.3390\/jcm8122140","volume":"8","author":"A Kubesch","year":"2019","unstructured":"Kubesch, A. et al. Short and long-term effectiveness of Ustekinumab in patients with Crohn\u2019s disease: Real-world data from a German IBD cohort. J. Clin. Med. 8(12), 2140. https:\/\/doi.org\/10.3390\/jcm8122140 (2019).","journal-title":"J. Clin. Med."},{"issue":"9","key":"25370_CR19","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1097\/MIB.0000000000000865","volume":"22","author":"N Singh","year":"2016","unstructured":"Singh, N. et al. Multi-center experience of vedolizumab effectiveness in pediatric inflammatory bowel disease. Inflamm. Bowel Dis. 22(9), 2121\u20132126. https:\/\/doi.org\/10.1097\/MIB.0000000000000865 (2016).","journal-title":"Inflamm. Bowel Dis."},{"issue":"9","key":"25370_CR20","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1111\/apt.14016","volume":"45","author":"C Ma","year":"2017","unstructured":"Ma, C. et al. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn\u2019s disease: Real world experience from a multicentre cohort. Aliment. Pharmacol. Ther. 45(9), 1232\u20131243. https:\/\/doi.org\/10.1111\/apt.14016 (2017).","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"3","key":"25370_CR21","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.cgh.2013.08.026","volume":"12","author":"GW Moran","year":"2014","unstructured":"Moran, G. W. et al. Phenotypic features of Crohn\u2019s disease associated with failure of medical treatment. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 12(3), 434-442.e1. https:\/\/doi.org\/10.1016\/j.cgh.2013.08.026 (2014).","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"issue":"11","key":"25370_CR22","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1016\/j.cgh.2016.02.016","volume":"14","author":"A Amiot","year":"2016","unstructured":"Amiot, A. et al. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 14(11), 1593-1601.e2. https:\/\/doi.org\/10.1016\/j.cgh.2016.02.016 (2016).","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"issue":"3","key":"25370_CR23","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/apt.14167","volume":"46","author":"A Amiot","year":"2017","unstructured":"Amiot, A. et al. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: A prospective multicentre cohort study. Aliment. Pharmacol. Ther. 46(3), 310\u2013321. https:\/\/doi.org\/10.1111\/apt.14167 (2017).","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"6","key":"25370_CR24","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.3390\/jcm10061242","volume":"10","author":"S Restellini","year":"2021","unstructured":"Restellini, S. & Afif, W. Update on TDM (therapeutic drug monitoring) with ustekinumab, vedolizumab and tofacitinib in inflammatory bowel disease. J. Clin. Med. 10(6), 1242. https:\/\/doi.org\/10.3390\/jcm10061242 (2021).","journal-title":"J. Clin. Med."},{"issue":"11","key":"25370_CR25","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMp1714229","volume":"378","author":"DS Char","year":"2018","unstructured":"Char, D. S., Shah, N. H. & Magnus, D. Implementing machine learning in health care\u2014Addressing ethical challenges. N. Engl. J. Med. 378(11), 981\u2013983. https:\/\/doi.org\/10.1056\/NEJMp1714229 (2018).","journal-title":"N. Engl. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25370-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25370-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25370-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T11:55:12Z","timestamp":1763726112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25370-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["25370"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-25370-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"11 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Coordinating Ethics Committee for Biomedical Research of Andalusia (CCEIBA, protocol code FPS-EII-2021-04, version 1 dated September 14, 2021). The Committee, acting under the authority of the Consejer\u00eda de Salud y Consumo, Secretar\u00eda General de Investigaci\u00f3n, Desarrollo e Innovaci\u00f3n en Salud, Direcci\u00f3n Gerencia del Servicio Andaluz de Salud, confirmed that the study meets the ethical requirements established by Royal Decree 957\/2020, the Declaration of Helsinki, and applicable regulations. Due to the retrospective nature of the study, the Coordinating Ethics Committee for Biomedical Research of Andalusia (CCEIBA) waived the need for obtaining informed consent. All research procedures were performed in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41350"}}